Alzheimer's Research UK

Gifts in Wills fund one in three of Alzheimer’s Research UK’s groundbreaking research projects.

By supporting Alzheimer’s Research UK with a gift in your Will, you could help fund the lifechanging research that will one day find a cure for dementia. Get your free gifts in Wills guide today to find out how you can offer hope to future generations: www.alzheimersresearchuk.org/free-wills-guide Together, we will end the heartbreak of dementia. 

Not all fairytales end the way we expect. But, together, we can change the ending.

This World Alzheimer's Day, Alzheimer's Research UK have launched their new campaign film, Change The Ending.

This powerful film, featuring a voiceover from Olivia Colman, puts the spotlight on the harsh reality of the impact of dementia and the urgent need to find a cure.

Stand with Alzheimer’s Research UK, and help change the ending.

Watch and share their new film: http://alzres.uk/foracure

Eli Lilly announced that their Alzheimer’s drug, donanemab, has successfully slowed memory and thinking decline in a rigorous phase 3 trial - another significant moment for dementia research.

Earlier this month a second drug for Alzheimer’s, donanemab, was shown to slow people’s cognitive decline in a rigorous phase 3 trial.

Donanemab was tested by its manufacturers Eli Lilly in a trial of nearly 1,200 people in the early stages of Alzheimer’s disease. Its findings suggest that the drug is effective in slowing the rate of decline of memory and thinking skills by 35%.

As with other drugs that have emerged recently, donanemab works by removing build-up of a protein called amyloid – a hallmark of Alzheimer’s - from the brain.

These effects appear modest and come with some significant side-effects – we need to see the full trial data to understand how these stack up against each other.

But the arrival of a second drug is a hugely promising time for dementia research, and these results prove that research can take us closer to a cure for diseases like Alzheimer’s. 

It also highlights the urgent need to prepare the NHS for delivering these new treatments, should they be approved by regulators. 

You can read our full comment to the story here: 

https://www.alzheimersresearchuk.org/second-alzheimers-drug-donanemab-succeeds-in-phase-3-trial/